X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PIRAMAL ENTERPRISES - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PIRAMAL ENTERPRISES BIOCON LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 36.7 36.5 100.4% View Chart
P/BV x 4.9 3.6 133.9% View Chart
Dividend Yield % 1.5 0.7 227.2%  

Financials

 BIOCON LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    BIOCON LTD
Mar-16
PIRAMAL ENTERPRISES
Mar-16
BIOCON LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs4961,065 46.5%   
Low Rs397805 49.3%   
Sales per share (Unadj.) Rs174.3383.0 45.5%  
Earnings per share (Unadj.) Rs44.855.1 81.3%  
Cash flow per share (Unadj.) Rs56.974.1 76.9%  
Dividends per share (Unadj.) Rs5.0017.50 28.6%  
Dividend yield (eoy) %1.11.9 59.9%  
Book value per share (Unadj.) Rs202.8719.9 28.2%  
Shares outstanding (eoy) m200.00172.56 115.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.4 104.9%   
Avg P/E ratio x10.017.0 58.7%  
P/CF ratio (eoy) x7.812.6 62.1%  
Price / Book Value ratio x2.21.3 169.4%  
Dividend payout %11.231.8 35.1%   
Avg Mkt Cap Rs m89,220161,344 55.3%   
No. of employees `0004.43.8 116.7%   
Total wages/salary Rs m6,36316,898 37.7%   
Avg. sales/employee Rs Th7,894.517,472.6 45.2%   
Avg. wages/employee Rs Th1,441.24,466.9 32.3%   
Avg. net profit/employee Rs Th2,029.72,512.8 80.8%   
INCOME DATA
Net Sales Rs m34,85466,099 52.7%  
Other income Rs m8452,425 34.9%   
Total revenues Rs m35,69968,524 52.1%   
Gross profit Rs m8,20018,723 43.8%  
Depreciation Rs m2,4233,274 74.0%   
Interest Rs m1029,388 1.1%   
Profit before tax Rs m6,5208,485 76.8%   
Minority Interest Rs m-7443 -22,545.5%   
Prior Period Items Rs m01,593 0.0%   
Extraordinary Inc (Exp) Rs m5,754457 1,259.9%   
Tax Rs m2,5691,032 249.0%   
Profit after tax Rs m8,9619,506 94.3%  
Gross profit margin %23.528.3 83.1%  
Effective tax rate %39.412.2 324.0%   
Net profit margin %25.714.4 178.8%  
BALANCE SHEET DATA
Current assets Rs m39,93247,488 84.1%   
Current liabilities Rs m16,276104,362 15.6%   
Net working cap to sales %67.9-86.0 -78.9%  
Current ratio x2.50.5 539.2%  
Inventory Days Days5441 131.9%  
Debtors Days Days8651 168.5%  
Net fixed assets Rs m39,10126,532 147.4%   
Share capital Rs m1,000345 289.8%   
"Free" reserves Rs m38,591114,024 33.8%   
Net worth Rs m40,556124,221 32.6%   
Long term debt Rs m20,72475,812 27.3%   
Total assets Rs m84,816308,356 27.5%  
Interest coverage x64.91.9 3,410.0%   
Debt to equity ratio x0.50.6 83.7%  
Sales to assets ratio x0.40.2 191.7%   
Return on assets %10.76.1 174.4%  
Return on equity %22.17.7 288.7%  
Return on capital %19.010.0 190.6%  
Exports to sales %30.717.2 178.9%   
Imports to sales %20.46.6 308.8%   
Exports (fob) Rs m10,71711,362 94.3%   
Imports (cif) Rs m7,1054,364 162.8%   
Fx inflow Rs m11,78914,435 81.7%   
Fx outflow Rs m8,3935,183 161.9%   
Net fx Rs m3,3969,253 36.7%   
CASH FLOW
From Operations Rs m5,264-67,773 -7.8%  
From Investments Rs m-9,540-8,768 108.8%  
From Financial Activity Rs m10,86776,199 14.3%  
Net Cashflow Rs m6,591-342 -1,924.9%  

Share Holding

Indian Promoters % 40.4 52.9 76.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 4.0 210.0%  
FIIs % 10.7 26.6 40.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 16.5 120.6%  
Shareholders   109,995 93,274 117.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   SHASUN PHARMA  WYETH LTD  TORRENT PHARMA  ALEMBIC LTD  DR. REDDYS LAB  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Aug 23, 2017 03:36 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS